Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Intangibles (2016 - 2025)

Historic Intangibles for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $4.2 million.

  • Lifecore Biomedical, Inc. \De\'s Intangibles changed 0.0% to $4.2 million in Q2 2025 from the same period last year, while for May 2025 it was $4.2 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $4.2 million for FY2025, which is 0.0% changed from last year.
  • Lifecore Biomedical, Inc. \De\'s Intangibles amounted to $4.2 million in Q2 2025, which was down 0.0% from $4.2 million recorded in Q1 2025.
  • Lifecore Biomedical, Inc. \De\'s Intangibles' 5-year high stood at $4.2 million during Q1 2021, with a 5-year trough of $4.2 million in Q1 2021.
  • Moreover, its 5-year median value for Intangibles was $4.2 million (2021), whereas its average is $4.2 million.
  • Over the last 5 years, Lifecore Biomedical, Inc. \De\'s Intangibles had its largest YoY gain of 0.0% in 2021, and its largest YoY loss of 8596.63% in 2021.
  • Quarter analysis of 5 years shows Lifecore Biomedical, Inc. \De\'s Intangibles stood at $4.2 million in 2021, then changed by 0.0% to $4.2 million in 2022, then changed by 0.0% to $4.2 million in 2023, then changed by 0.0% to $4.2 million in 2024, then changed by 0.0% to $4.2 million in 2025.
  • Its Intangibles was $4.2 million in Q2 2025, compared to $4.2 million in Q1 2025 and $4.2 million in Q4 2024.